Novel transgenic mouse models develop retinal changes associated with early diabetic retinopathy similar to those observed in rats with diabetes mellitus

Experimental Eye Research

Volumn 119, Issue , 2014, Pages 77-87

  Guo, Changmei ^a   Zhang, Zifeng ^a   Zhang, Peng ^a   Makita, Jun ^a   Kawada, Hiroyoshi ^a   Blessing, Karen ^a   Kador, Peter F ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aldose reductase; Cell signaling P ERK1 2, P SAPK JNK, P Akt; Diabetic rats; Diabetic retinopathy; Green fluorescent proteins; Growth factors VEGF, bFGF, TGF ; Retinal vascular changes; Transgenic diabetic mouse models

Indexed keywords

ALDEHYDE REDUCTASE; ALPHA SMOOTH MUSCLE ACTIN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; ELASTASE; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; SOMATOMEDIN C; SORBITOL; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CAPILLARY; CONTROLLED STUDY; CROSS BREEDING; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; RAT; RETINA DISEASE; RETINA NEUROEPITHELIAL LAYER; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSGENIC MOUSE; VASCULAR TISSUE; WESTERN BLOTTING;

ALDOSE REDUCTASE; CELL SIGNALING P-ERK1/2, P-SAPK/JNK, P-AKT; DIABETIC RATS; DIABETIC RETINOPATHY; GREEN FLUORESCENT PROTEINS; GROWTH FACTORS VEGF, BFGF, TGF-Β; RETINAL VASCULAR CHANGES; TRANSGENIC DIABETIC MOUSE MODELS;

ALDEHYDE REDUCTASE; ANIMALS; BLOTTING, WESTERN; CAPILLARIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE PROGRESSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, TRANSGENIC; RATS; RATS, SPRAGUE-DAWLEY; RETINA; TIME FACTORS;

EID: 84891649533     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.12.009     Document Type: Article

References (83)

1. Abhary S., Hewitt A.W., Burdon K.P., Craig J.E. Asystematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009, 58:2137-2147.
2. Akagi Y., Kador P.F., Kuwabara T., Kinoshita J.H. Aldose reductase localization in human retinal mural cells. Invest. Ophthalmol. Vis. Sci. 1983, 24:1516-1519.
3. Akagi Y., Terubayashi H., Millen J., Kador P.F., Kinoshita J.H. Aldose reductase localization in dog retinal mural cells. Curr. Eye. Res. 1986, 5:883-886.
4. Akagi Y., Yajima Y., Kador P.F., Kuwabara T., Kinoshita J.H. Localization of aldose reductase in the human eye. Diabetes 1984, 33:562-566.
5. Amano S., Yamagishi S., Kato N., Inagaki Y., Okamoto T., Makino M., Taniko K., Hirooka H., Jomori T., Takeuchi M. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem. Biophys. Res. Commun. 2002, 299:183-188.
6. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-523.
7. Asnaghi V., Gerhardinger C., Hoehn T., Adeboje A., Lorenzi M. Arole for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003, 52:506-511.
8. Beltramo E., Porta M. Pericyte loss in diabetic retinopathy: mechanisms and consequences. Curr. Med. Chem. 2013, 20:3218-3225.
9. Cai J., Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond.) 2002, 16:242-260.
10. Chantelau E., Kimmerle R., Meyer-Schwickerath R. Insulin, insulin analogues and diabetic retinopathy. Arch. Physiol. Biochem. 2008, 114:54-62.
11. Cheung A.K., Fung M.K., Lo A.C., Lam T.T., So K.F., Chung S.S., Chung S.K. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 2005, 54:3119-3125.
12. Chung S.S., Chung S.K. Genetic analysis of aldose reductase in diabetic complications. Curr. Med. Chem. 2003, 10:1375-1387.
13. Cogan D.G., Toussaint D., Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch. Ophthalmol. 1961, 66:366-378.
14. Cusick M., Chew E.Y., Ferris F., Cox T.A., Chan C.C., Kador P.F. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch. Ophthalmol. 2003, 121:1745-1751.
15. D.C.C.T Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995, 102:647-661.
16. Dagher Z., Park Y.S., Asnaghi V., Hoehn T., Gerhardinger C., Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004, 53:2404-2411.
17. Demaine A., Cross D., Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest. Ophthalmol. Vis. Sci. 2000, 41:4064-4068.
18. Dihazi H., Dihazi G.H., Mueller C., Lahrichi L., Asif A.R., Bibi A., Eltoweissy M., Vasko R., Mueller G.A. Proteomics characterization of cell model with renal fibrosis phenotype: osmotic stress as fibrosis triggering factor. J.Proteomics 2011, 74:304-318.
19. dos Santos K.G., Canani L.H., Gross J.L., Tschiedel B., Souto K.E., Roisenberg I. The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes. Mol. Genet. Metab. 2006, 88:280-284.
20. Drenckhahn D., Groschel-Stewart U. Localization of myosin and actin in ocular nonmuscle cells. immunofluorescence-microscopic, biochemical, and electron-microscopic studies. Cell Tissue Res. 1977, 181:493-503.
21. Ejaz S., Chekarova I., Ejaz A., Sohail A., Lim C.W. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes. Metab. 2008, 10:53-63.
22. Frank R.N. Treating diabetic retinopathy by inhibiting growth factor pathways. Curr. Opin. Invest. Drugs 2009, 10:327-335.
23. Frank R.N., Amin R., Kennedy A., Hohman T.C. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch. Ophthalmol. 1997, 115:1036-1047.
24. Frey T., Antonetti D.A. Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxid. Redox Signal 2011, 15:1271-1284.
25. Gacka M., Adamiec J. [The role of transforming growth factor-beta in the pathogenesis of diabetic retinopathy]. Przegl. Lek. 2006, 63:296-298.
26. Gaynes B.I., Watkins J.B. Comparison of glucose, sorbitol and fructose accumulation in lens and liver of diabetic and insulin-treated rats and mice. Comp. Biochem. Physiol. B 1989, 92:685-690.
27. Grossniklaus H.E., Kang S.J., Berglin L. Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 2010, 29:500-519.
28. Hall A.P. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol. Pathol. 2006, 34:763-775.
29. Hammes H.P., Lin J., Renner O., Shani M., Lundqvist A., Betsholtz C., Brownlee M., Deutsch U. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002, 51:3107-3112.
30. Hattori T., Matsubara A., Taniguchi K., Ogura Y. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina invivo. Curr. Eye Res. 2010, 35:146-154.
31. Henry D.N., Frank R.N., Hootman S.R., Rood S.E., Heilig C.W., Busik J.V. Glucose-specific regulation of aldose reductase in human retinal pigment epithelial cells invitro. Invest. Ophthalmol. Vis. Sci. 2000, 41:1554-1560.
32. Hickman F., Fariss R., Pagan-Mercado, Yamamoto T., Wawrousek E., Yabe-Nishimura C., Tsai J. Characterization of retinal Neurons Over-expressing human aldose reductase in Smaa-har mice. Invest. Opthalmol. Vis. Sci. 2002, 43:742.
33. 2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 2006, 55:1946-1953.
34. Joussen A.M., Doehmen S., Le M.L., Koizumi K., Radetzky S., Krohne T.U., Poulaki V., Semkova I., Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 2009, 15:1418-1428.
35. Kador P.F., Akagi Y., Takahashi Y., Ikebe H., Wyman M., Kinoshita J.H. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch. Ophthalmol. 1990, 108:1301-1309.
36. Kador P.F., Randazzo J., Blessing K., Makita J., Zhang P., Yu K., Hosoya K., Terasaki T. Polyol formation in cell lines of rat retinal capillary pericytes and endothelial cells (TR-rPCT and TR-iBRB). J.Ocul. Pharmacol. Ther. 2009, 25:299-308.
37. Kador P.F., Takahashi Y., Akagi Y., Blessing K., Randazzo J., Wyman M. Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs. J.Ocul. Pharmacol. Ther. 2007, 23:63-69.
38. Kador P.F., Takahashi Y., Wyman M., Ferris F. Diabeteslike proliferative retinal changes in galactose-fed dogs. Arch. Ophthalmol. 1995, 113:352-354.
39. Kador P.F., Zhang P., Makita J., Zhang Z., Guo C., Randazzo J., Kawada H., Haider N., Blessing K. Novel diabetic mouse models as tools for investigating diabetic retinopathy. PLoS One 2012, 7:e49422.
40. Katakami N., Kaneto H., Takahara M., Matsuoka T.A., Imamura K., Ishibashi F., Kanda T., Kawai K., Osonoi T., Matsuhisa M., Kashiwagi A., Kawamori R., Shimomura I., Yamasaki Y. Aldose reductase C-106T gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2011, 92:e57-60.
41. Khan Z.A., Chakrabarti S. Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp. Diabetes Res. 2007, 31867.
42. Kivela T., Uusitalo M. Structure, development and function of cytoskeletal elements in non-neuronal cells of the human eye. Prog. Retin. Eye Res. 1998, 17:385-428.
43. Kumaramanickavel G., Sripriya S., Ramprasad V.L., Upadyay N.K., Paul P.G., Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet. 2003, 24:41-48.
44. Kuwabara T., Carroll J.M., Cogan D.G. Retinal vascular patterns. III. Age, hypertension, absolute glaucoma, injury. Arch. Ophthalmol. 1961, 65:708-716.
45. Lee C.A., Li G., Patel M.D., Petrash J.M., Benetz B.A., Veenstra A., Amengual J., Von Lintig J., Burant C., Tang J., Kern T.S. Diabetes-induced impairment in visual function in mice: contributions of p38 MAPK, RAGE, leukocytes, and aldose reductase. Invest. Ophthalmol. Vis. Sci. 2013, 13:11659. [Epub ahead of print].
46. Llewelyn J.G., Thomas P.K., Mirrlees D.J. Aldose reductase activity and myo-inositol levels in sciatic nerve and dorsal root ganglia of the diabetic mutant mouse [C57/BL/Ks (db/db)]. Metabolism 1991, 40:1084-1087.
47. Makita J., Hosoya K., Zhang P., Kador P.F. Response of rat retinal capillary pericytes and endothelial cells to glucose. J.Ocul. Pharmacol. Ther. 2011, 27:7-15.
48. Markus H.B., Raducha M., Harris H. Tissue distribution of mammalian aldose reductase and related enzymes. Biochem. Med. 1983, 29:31-45.
49. Matsumoto T., Ono Y., Kuromiya A., Toyosawa K., Ueda Y., Bril V. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. J.Pharmacol. Sci. 2008, 107:340-348.
50. Miwa K., Nakamura J., Hamada Y., Naruse K., Nakashima E., Kato K., Kasuya Y., Yasuda Y., Kamiya H., Hotta N. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res. Clin. Pract. 2003, 60:1-9.
51. Mulhern M.L., Madson C.J., Danford A., Ikesugi K., Kador P.F., Shinohara T. The unfolded protein response in lens epithelial cells from galactosemic rat lenses. Invest. Ophthalmol. Vis. Sci. 2006, 47:3951-3959.
52. Murata M., Ohta N., Fujisawa S., Tsai J.Y., Sato S., Akagi Y., Takahashi Y., Neuenschwander H., Kador P.F. Selective pericyte degeneration in the retinal capillaries of galactose-fed dogs results from apoptosis linked to aldose reductase-catalyzed galactitol accumulation. J.Diabetes Complications 2002, 16:363-370.
53. Naruse K., Nakamura J., Hamada Y., Nakayama M., Chaya S., Komori T., Kato K., Kasuya Y., Miwa K., Hotta N. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp. Eye Res. 2000, 71:309-315.
54. Neuenschwander H., Takahashi Y., Kador P.F. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J.Ocul. Pharmacol. Ther. 1997, 13:517-528.
55. Nicholson B.P., Schachat A.P. Areview of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:915-930.
56. Oates P.J. Polyol pathway and diabetic peripheral neuropathy. Int. Rev. Neurobiol. 2002, 50:325-392.
57. Obrosova I.G., Drel V.R., Kumagai A.K., Szabo C., Pacher P., Stevens M.J. Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models. Diabetologia 2006, 49:2525-2533.
58. Obrosova I.G., Kador P.F. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12:373-385.
59. Obrosova I.G., Minchenko A.G., Vasupuram R., White L., Abatan O.I., Kumagai A.K., Frank R.N., Stevens M.J. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003, 52:864-871.
60. Olmos P., Futers S., Acosta A.M., Siegel S., Maiz A., Schiaffino R., Morales P., Diaz R., Arriagada P., Claro J.C., Vega R., Vollrath V., Velasco S., Emmerich M. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res. Clin. Pract. 2000, 47:169-176.
61. Paques M., Massin P., Gaudric A. Growth factors and diabetic retinopathy. Diabetes Metab. 1997, 23:125-130.
62. Peterson M.J., Page M.G., Just L.J., Aldinger C.E., Malone J.I. Applicability of red blood cell sorbitol measurements to monitor the clinical activity of sorbinil. Metabolism 1986, 35:93-95.
63. Petrovic M.G., Peterlin B., Hawlina M., Petrovic D. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in caucasians. J.Diabetes Complications 2005, 19:70-73.
64. Richeti F., Noronha R.M., Waetge R.T., de Vasconcellos J.P., de Souza O.F., Kneipp B., Assis N., Rocha M.N., Calliari L.E., Longui C.A., Monte O., de Melo M.B. Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol. Vis. 2007, 13:740-745.
65. Robinson R., Barathi V.A., Chaurasia S.S., Wong T.Y., Kern T.S. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis. Model. Mech. 2012, 5:444-456.
66. Robison W.G. Galactosemic Animal Models 2000, Harwood Academic Publishers, Amsterdam.
67. Robison W.G., McCaleb M.L., Feld L.G., Michaelis O.E.t, Laver N., Mercandetti M. Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats. Curr. Eye Res. 1991, 10:339-350.
68. Robison W.G., Laver N.M., Lou M.F. The role of aldose reductase in diabetic retinopathy: prevention and intervention studies. Progress in Retinal and Eye Research 1995, 593-639. Pergamon, Oxford. N.N. Osborne, G.J. Chader (Eds.).
69. Ruberte J., Ayuso E., Navarro M., Carretero A., Nacher V., Haurigot V., George M., Llombart C., Casellas A., Costa C., Bosch A., Bosch F. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J.Clin. Invest. 2004, 113:1149-1157.
70. Sato S., Secchi E.F., Lizak M.J., Fukase S., Ohta N., Murata M., Tsai J.Y., Kador P.F. Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Invest. Ophthalmol. Vis. Sci. 1999, 40:697-704.
71. Song E., Dong Y., Sui D.M., Zhao X.Z., Wu J.X. Effects of vascular endothelial growth factor and basic fibroblast growth factor in early stage diabetic retinopathy and their molecular pathological mechanism]. Zhonghua Yi Xue Za Zhi 2003, 83:996-999.
72. Stitt A.W., Lois N., Medina R.J., Adamson P., Curtis T.M. Advances in our understanding of diabetic retinopathy. Clin. Sci. (Lond.) 2013, 125:1-17.
73. Szaflik J.P., Majsterek I., Kowalski M., Rusin P., Sobczuk A., Borucka A.I., Szaflik J., Blasiak J. Association between sorbitol dehydrogenase gene polymorphisms and type 2 diabetic retinopathy. Exp. Eye Res. 2008, 86:647-652.
74. Takahashi Y., Augustin W., Wyman M., Kador P.F. Quantitative analysis of retinal vessel changes in galactose-fed dogs. J.Ocul. Pharmacol. 1993, 9:257-269.
75. Takamura Y., Tomomatsu T., Kubo E., Tsuzuki S., Akagi Y. Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells. Invest. Ophthalmol. Vis. Sci. 2008, 49:3216-3223.
76. Uthra S., Raman R., Mukesh B.N., Rajkumar S.A., Kumari P., Lakshmipathy P., Gnanamoorthy P., Sharma T., McCarty C.A., Kumaramanickavel G. Diabetic retinopathy: validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort. Ophthalmic Genet. 2010, 31:244-251.
77. Van Geest R.J., Klaassen I., Vogels I.M., Van Noorden C.J., Schlingemann R.O. Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy?. Invest. Ophthalmol. Vis. Sci. 2010, 51:1857-1865.
78. Wang Y., Ng M.C., Lee S.C., So W.Y., Tong P.C., Cockram C.S., Critchley J.A., Chan J.C. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003, 26:2410-2415.
79. Wang Y.L., Hui Y.N. The problems that should be noticed in choosing animal models with diabetic retinopathy. Zhonghua Yan Ke Za Zhi 2012, 48:587-590.
80. Yokota T., Kawakami Y., Nagai Y., Ma J.X., Tsai J.Y., Kincade P.W., Sato S. Bone marrow lacks a transplantable progenitor for smooth muscle type alpha-actin-expressing cells. Stem cells 2006, 24:13-22.
81. Yoshioka M., Kayo T., Ikeda T., Koizumi A. Anovel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997, 46:887-894.
82. Zhang P., Xing K., Randazzo J., Blessing K., Lou M.F., Kador P.F. Osmotic stress, not aldose reductase activity, directly induces growth factors and MAPK signaling changes during sugar cataract formation. Exp. Eye Res. 2012, 101:36-43.
83. Zhang P., Zhang Z., Kador P.F. Polyol effects on growth factors and MAPK signaling in rat retinal capillary cells. J.Ocul. Pharmacol. Ther. 2013 Nov 20, (in press), (Epub ahead of print).